Table 2.
General characteristic of the included studies.
| Author | All cause death | Cardiovascular death | Myocardial infarction | Stent thrombosis | Any revascularisation | Bleeding definition | Major bleeding | Fatal bleeding | Intracranial bleeding | Follow up |
|---|---|---|---|---|---|---|---|---|---|---|
| Bonaca 2014 | 326/7050 vs 326/7067 | 182/7050 vs 210/7067 | 275/7050 vs 338/7067 | TIMI | 127/6988 vs 54/6996 | 29/6988 vs 23/6996 | 36 mo | |||
| Collet 2014 | 7/635 vs 9/624 | 9/635 vs 9/624 | 0/635 vs 3/624 | 8/635 vs 3/624 | TIMI | 0/635 vs 0/624 | 0/635 vs 0/624 | 17 mo | ||
| Connolly 2018 | 262/8313 vs 339/8261 | 10/695 vs 14/690 | 11/695 vs 16/690 | 6/695 vs 1/690 | 35/695 vs 35/690 | TIMI | 4/695 vs 4/690 | 1/695 vs 0/690 | 1/695 vs 2/690 | 44 mo |
| Helft 2016 | 16/695 vs 24/690 | 174/7045 vs 210/7067 | 285/7045 vs 338/7067 | 115/6958 vs 54/6996 | 11/6958 vs 12/6996 | 28/6958 vs 23/6996 | ||||
| Koo 2021 | 51/2710 vs 36/2728 | 19/2710 vs 14/2728 | 18/2710 vs 28/2728 | 56/2710 vs 69/2728 | BARC type ≥ 3 | 33/2710 vs 53/2728 | 4/2710 vs 17/2728 | 24 mo | ||
| Lee 2014 | 46/2531 vs 32/2514 | 28/2531 vs 19/2514 | 19/2531 vs 27/2514 | 7/2513 vs 11/2514 | 81/2531 vs 65/2514 | TIMI | 34/2531 vs 24/2514 | 1/2513 vs 4/2514 | 5/2531 vs 3/2514 | 24 mo |
| Mauri 2014 | 98/5020 vs 74/4941 | 45/5020 vs 47/4941 | 99/5020 vs 198/4941 | 19/5020 vs 65/4941 | BARA type ≥ 3 | 129/4713 vs 4/4650 | 7/4713 vs 44/4650 | 13/4713 vs 9/4650 | 18 mo | |
| Park 2023 | 11/320 vs 17/317 | 4/320 vs 11/317 | 2/320 vs 17/317 | 1/320 vs 1/317 | 14/320 vs 15/317 | TIMI | 7/320 vs 17/317 | 1/320 vs 0/317 | 12 mo | |
| Park 2019 | 20/1357 vs 13/1344 | 13/1357 vs 8/1344 | 10/1357 vs 7/1344 | 5/1357 vs 4/1344 | 36/1357 vs 26/1344 | TIMI | 3/1357 vs 1/1344 | 0/1357 vs 0/1344 | 24 mo | |
| Steg 2019 | 579/9619 vs 592/9601 | 364/9619 vs 357/9601 | 274/9619 vs 328/9601 | 828/9619 vs 879/9601 | TIMI | 206/9562 vs 100/9531 | 17/9562 vs 46/9531 | 70/9562 vs 46/9531 | 39.9 mo |
A, Aspirin, B, Aspirin + clopidogrel, C, Aspirin + clopidogrel + cilostazol, D, Clopidogrel/prasugrel + aspirin; E, Aspirin + rivaoxaban 2.5 mg; F, Aspirin + ticagrelor 60 mg; G, Aspirin + ticagrelor 90 mg; H, clopidogrel, I, Rivroxaban 5 mg.